BIAF (bioAffinity Technologies) Total Operating Expense: $13.44 Mil (TTM As of Mar. 2026)


BIAF bioAffinity Technologies Inc BIAF
44 GF Score
Price $0.76
GF Value $4.27
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is bioAffinity Technologies Total Operating Expense?

bioAffinity Technologies BIAF -1.48% 44 Total Operating Expense is $13.44 Mil as of Mar. 2026. GuruFocus rates BIAF with a GF Score™ of 44/100 and a GF Value™ of $4.27 (Possible Value Trap). The stock has 3 warning signs investors should review.

bioAffinity Technologies's Total Operating Expense for the three months ended in Mar. 2026 was $4.04 Mil. bioAffinity Technologies's Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was $13.44 Mil.

bioAffinity Technologies Total Operating Expense Related Terms

bioAffinity Technologies Total Operating Expense Historical Data

* Premium members only.

The historical data trend for bioAffinity Technologies's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

bioAffinity Technologies Total Operating Expense Chart

bioAffinity Technologies Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Operating Expense
Get a 7-Day Free Trial 2.21 4.02 8.77 12.33 12.51

bioAffinity Technologies Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.11 2.77 2.80 3.83 4.04
BIAF
44GF Score
bioAffinity Technologies Inc BIAF
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

bioAffinity Technologies Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $13.44 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of $13.44 Mil mean?
bioAffinity Technologies (BIAF) has a Total Operating Expense of $13.44 Mil as of Mar. 2026. Total operating expense is the primary recurring expense associated with central operations. View historical data on bioAffinity Technologies and its competitors.
Is bioAffinity Technologies' Total Operating Expense too high?
bioAffinity Technologies' current Total Operating Expense is $13.44 Mil. Overall, bioAffinity Technologies has a GF Score™ of 44/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does bioAffinity Technologies' Total Operating Expense compare to NDRA and ISPC?
bioAffinity Technologies' Total Operating Expense of $13.44 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Medical Diagnostics & Research company?
A good Total Operating Expense depends on the Medical Diagnostics & Research industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on bioAffinity Technologies and its competitors. bioAffinity Technologies's current Total Operating Expense is $13.44 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is bioAffinity Technologies stock overvalued right now?
Based on GuruFocus' analysis, bioAffinity Technologies (BIAF) is currently considered Possible Value Trap. The stock's GF Value™ is $4.27, compared to a current price of $0.76 — trading 82.2% below its estimated fair value. The current Total Operating Expense is $13.44 Mil. bioAffinity Technologies' overall GF Score™ is 44/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For bioAffinity Technologies (BIAF), the current Total Operating Expense is $13.44 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is bioAffinity Technologies (BIAF) Overvalued in 2026?

Based on GuruFocus' analysis, bioAffinity Technologies stock appears to be undervalued. The current stock price of $0.76 is trading 82.2% below its estimated GF Value™ of $4.27. GuruFocus considers bioAffinity Technologies to be Possible Value Trap.

Key valuation signals for BIAF:

  • Total Operating Expense: $13.44 Mil
  • GF Value™: $4.27 vs. price of $0.76 (82.2% below fair value)
  • GF Score™: 44/100 with 3 warning signs

No single metric tells the full story. See the BIAF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

bioAffinity Technologies Business Description

Address 3300 Nacogdoches Road, Suite 216, San Antonio, TX, USA, 78217
bioAffinity Technologies Inc develops noninvasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis informed by machine learning, a form of artificial intelligence (AI). Its first commercial diagnostic test, CyPath Lung, identifies and analyzes cell populations using flow cytometry, including cancer and cancer-related cells, that indicate a malignancy in the lung. It is developing its flow cytometry platform to address the need to identify patients who can benefit from new and emerging therapies for asthma and chronic obstructive pulmonary disease with noninvasive precision diagnostic tests. The company is organized in two operating segments, Diagnostic Research and Development and Laboratory Services.
44GF Score

Get the complete analysis for BIAF

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.76
Price
$4.27
GF Value